Supplementary Figure 2 from Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Authors :: Winald R. Gerritsen
Sarita Dubey
Elwyn Loh
Yizhou Jiang
Kelly S. Oliner
Rui Tang
Min Zhu
Sandy Srinivas
Jean-Pascal Machiels
Frédéric Forget
Karim Fizazi
Gwenaëlle Gravis
Joel Picus
Joshi Alumkal
Siobhan Ng
Mark Rosenthal
Charles J. Ryan
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: PDF file - 1418K, Forest plot of the treatment effect of rilotumumab compared with placebo on OS by covariate subgroups in the intention-to-treat analysis set. ECOG, Eastern Cooperative Oncology Group; PD, progressive disease.

Tools